The inauguration in Iran of an anti-COVID-19 vaccine production plant named PastoCorona makes this country the first to industrially manufacture one of Cuba’s immunogens against SARS-COV-2, according to a Twitter post by the Finlay Vaccine Institute (IFV), which reached an agreement to transfer, to the Pasteur Institute there, the technology its scientists developed to create the Soberana 02 vaccine.
The opening of the facility took place within the context of the XVIII session of the Cuba-Iran Intergovernmental Commission, May 15, attended by Deputy Prime Minister Ricardo Cabrisas, and Iran’s Minister of Health, Bahram Einollahi, also reported on Twitter by Cuba’s pharmaceutical state enterprise group, BioCubaFarma.
The IFV noted that Soberana 02 – the first conjugate vaccine against COVID-19 worldwide – will be marketed in Iran as PastuCovac.
According to a press release from Tehran, during the Intergovernmental Commission meeting, Cabrisas expressed the Cuban government’s desire to deepen and expand economic relations with Iran in a variety of sectors, including health, energy, food production and agriculture.
He condemned the unilateral coercive measures adopted by the U.S. government against the Islamic Republic of Iran, and thanked the Iranian Foreign Ministry for its opposition to the economic, commercial and financial blockade imposed by the U.S. on Cuba, as well as its condemnation of Cuba’s inclusion on the State Department’s spurious list of state sponsors of terrorism.
Bahram Einollahi, for his part, expressed satisfaction with the excellent state of political relations achieved by the two nations, and reaffirmed the interest of his government in increasing economic, commercial, financial and cooperative ties.
